Bimatoprost/Timolol Versus Travoprost/Timolol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01542710
Recruitment Status : Completed
First Posted : March 2, 2012
Last Update Posted : March 2, 2012
Information provided by (Responsible Party):
Tamer A Macky, Kasr El Aini Hospital

Brief Summary:
The purpose of this study is to compare 2 fixed combination medications in intraocular pressure lowering.

Condition or disease Intervention/treatment Phase
Glaucoma Drug: Ganfort Drug: Duotrav Not Applicable

Detailed Description:

PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.

METHODS: Patients with primary open angle glaucoma (POAG) were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measures were the mean change in IOP from baseline

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study
Study Start Date : January 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: Glaucoma fixed Combination Medications Drug: Ganfort
Bimatoprost/Timolol fixed combination
Other Name: Bimatoprost/Timolol vs Travoprost/Timolol fixed combination

Drug: Duotrav
Fixed combination of Travoprost and Timolol

Primary Outcome Measures :
  1. Percentage of drop of intraocular pressures from baseline. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Glaucoma

Exclusion Criteria:

  • No other ocular diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01542710

Kasr El Aini Hospital
Cairo, Egypt
Sponsors and Collaborators
Kasr El Aini Hospital
Principal Investigator: Tamer A Macky, MD FRCS Cairo University

Responsible Party: Tamer A Macky, Assistant Professor, Kasr El Aini Hospital Identifier: NCT01542710     History of Changes
Other Study ID Numbers: Fixed Glaucoma Medications
GANDUO-2011 ( Other Identifier: Cairo University )
First Posted: March 2, 2012    Key Record Dates
Last Update Posted: March 2, 2012
Last Verified: January 2011

Additional relevant MeSH terms:
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents